Tag Archives: Intellectual Property

What International Trade Agreements Have to Do with Innovation

Attendees

Innovation is not just the life-blood of the biotech industry, it is the very premise of the BIO International Convention. So what is a panel on international trade doing here? Answering this question is the task panel moderator, Richard Bergstrom, Director General, EFPIA gave to participants in the session TTIP: Can US and the EU Lead the Way in Setting New Global Benchmarks for IP, Regulatory and Market Access Issues; and each provided a piece Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Protecting your IP Overseas

shutterstock_2103563

According to the World Intellectual Property Organization (WIPO), nearly 100,000 biotechnology and pharmaceutical patent applications are filed worldwide each year, and the trend appears to be rising. As you’ve likely experienced, filing patent applications can be very complex, with different laws, deadlines and languages requiring highly technical translators for most countries in which you’re seeking protection. As a result, companies seeking IP protection often outsource their domestic and foreign patent filings to service providers to Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

US Public Organizations Leading Genomic Research, with Europe and Asia Catching Up

Gareth Williams  - Head Shot (March 2013) C High(2146527_1)

Since before the mapping of the human genome just over a decade ago, we have been applying our growing understanding the genome and associated –omes to medical and industrial uses. Thanks to this understanding, we now have the ability to pinpoint a specific genetic variation in a specific patient which can predict sensitivity to certain drugs. But where is innovation in genomics coming from? And where is it going? What roles are emerging markets playing? Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Supreme Court Enunciates New Indefiniteness Standard

Noonan

The Supreme Court has once again reversed a decision by the Federal Circuit, in this case involving the proper standard for finding claims indefinite. The case, Nautilus, Inc. v. Biosig Instruments, Inc., overturned the Federal Circuit’s “insolubly ambiguous” test and substituted its own “reasonable certainty” test.  The Court left intentionally unclear the precise ways in which their new test will differ from the Federal Circuit’s abrogated test, leaving it to the lower court to decide Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Patent Reform Legislation Off The Table For Now

Williams

If the mainstream media is to be believed, the patent system is broken.  This notion is frequently blamed on the perceived increase in so-called patent assertion entities (“PAEs”), referred to derogatorily as “patent trolls.”  More often than not, these media reports cite to a limited number of examples illustrating the perceived abuses, and reach the conclusion that patents are stifling innovation.  And, even though there has been serious disagreement about the extent of the problem, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,